Tevogen Bio’s (TVGN) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Tevogen Bio (NASDAQ:TVGN) in a report published on Tuesday morning,Benzinga reports. They currently have a $10.00 price target on the stock.

Tevogen Bio Price Performance

Shares of Tevogen Bio stock opened at $1.29 on Tuesday. The business’s fifty day moving average is $1.09 and its two-hundred day moving average is $1.22. Tevogen Bio has a fifty-two week low of $0.26 and a fifty-two week high of $3.09.

Insider Buying and Selling

In related news, insider Neal Flomenberg sold 70,384 shares of the company’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $1.09, for a total transaction of $76,718.56. Following the completion of the sale, the insider now directly owns 3,898,828 shares of the company’s stock, valued at approximately $4,249,722.52. This represents a 1.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have sold 406,510 shares of company stock valued at $446,763. 73.24% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Tevogen Bio during the 4th quarter valued at about $38,000. JPMorgan Chase & Co. grew its position in Tevogen Bio by 74.2% in the fourth quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock valued at $40,000 after acquiring an additional 16,695 shares in the last quarter. Barclays PLC raised its stake in shares of Tevogen Bio by 39.2% during the fourth quarter. Barclays PLC now owns 45,600 shares of the company’s stock valued at $48,000 after purchasing an additional 12,847 shares during the period. XTX Topco Ltd acquired a new position in shares of Tevogen Bio during the fourth quarter worth $55,000. Finally, Nuveen LLC purchased a new position in shares of Tevogen Bio in the first quarter valued at $97,000.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.